tirzepatide wada and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism The World Anti-Doping Agency Is

Our study included 308 patients with T2D who used GLP1-RAs continuously, for 12 months and control group treated with conventional anti-diabetic regimens without GLP-1RAs

But if youre not sure, you can always speak to one of our clinicians for personalised advice. Aniyah Mansuri , weight loss expert at myBMI Sources Our Medicines

Clinical trial data from the SURPASS trials showed that tirzepatide users experienced modest reductions in resting heart rate over 52 weeks, despite initial fluctuations

"It can result in significant long-term weight loss." She also pointed to structured lifestyle programs that blend exercise, healthy eating, and habit tracking for lasting results